A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers

The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP) inhibitors have been established as a standard o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tinker, Anna V., Altman, Alon D., Bernardini, Marcus Q., Ghatage, Prafull, Gien, Lilian T., Provencher, Diane, Salvador, Shannon, Doucette, Sarah, Oza, Amit M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221681/
https://www.ncbi.nlm.nih.gov/pubmed/35735457
http://dx.doi.org/10.3390/curroncol29060348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221681/
https://www.ncbi.nlm.nih.gov/pubmed/35735457
http://dx.doi.org/10.3390/curroncol29060348

Ejemplares similares